# IMJUDO
> **BLA761270** · Biologics License Application · Sponsor: ASTRAZENECA AB · Approved 2022-11-10
## Drug
- **FDA Application Number:** BLA761270
- **Application type:** Biologics License Application
- **Brand name:** IMJUDO
- **Generic name:** Tremelimumab-Actl
- **Active ingredients:** TREMELIMUMAB-ACTL
- **Dosage form:** INJECTABLE
- **Route:** INTRAVENOUS
- **Marketing status:** Prescription
- **Sponsor:** ASTRAZENECA AB
- **First approval:** 2022-11-10
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270)
---
*AI Analytics · CC0 1.0*